EGFR (K716A)
Sign in to save this workspaceEGFR · Variant type: point · HGVS: p.K716A
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Cabozantinib | 100.0% | 0.0% | 92.73 |
| 2 | Neratinib | 98.6% | 1.4% | 93.18 |
| 3 | Osimertinib | 98.5% | 1.5% | 97.24 |
| 4 | Mobocertinib | 97.7% | 2.3% | 97.22 |
| 5 | Canertinib | 96.3% | 3.7% | 96.49 |
| 6 | Lazertinib | 92.5% | 7.5% | 97.47 |
| 7 | Erlotinib | 91.0% | 9.0% | 99.75 |
| 8 | Zanubrutinib | 87.8% | 12.2% | 98.24 |
| 9 | Vandetanib | 85.1% | 14.9% | 95.74 |
| 10 | Fostamatinib | 79.9% | 20.1% | 96.74 |
| 11 | Pralsetinib | 55.7% | 44.3% | 93.43 |
| 12 | Lenvatinib | 49.0% | 51.0% | 97.74 |
| 13 | Dacomitinib | 47.5% | 52.5% | 97.99 |
| 14 | Vemurafenib | 28.6% | 71.4% | 96.49 |
| 15 | Selumetinib | 28.6% | 71.4% | 100.00 |
| 16 | Defactinib | 28.2% | 71.8% | 92.68 |
| 17 | Pacritinib | 27.0% | 73.0% | 88.64 |
| 18 | Infigratinib | 22.8% | 77.2% | 98.24 |
| 19 | Apatinib | 20.1% | 79.9% | 97.73 |
| 20 | Imatinib | 19.3% | 80.7% | 99.00 |
| 21 | Umbralisib | 19.2% | 80.8% | 98.74 |
| 22 | Leniolisib | 18.0% | 82.0% | 100.00 |
| 23 | Everolimus | 17.1% | 82.9% | 100.00 |
| 24 | Pazopanib | 17.0% | 83.0% | 97.49 |
| 25 | Ribociclib | 16.6% | 83.4% | 99.25 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Cabozantinib | 100.0% | — | — |
| Neratinib | 98.6% | 100.0% | -1.4% |
| Osimertinib | 98.5% | 99.1% | -0.6% |
| Mobocertinib | 97.7% | 100.0% | -2.3% |
| Canertinib | 96.3% | 98.4% | -2.1% |
| Lazertinib | 92.5% | 100.0% | -7.5% |
| Erlotinib | 91.0% | 99.4% | -8.4% |
| Zanubrutinib | 87.8% | 88.2% | -0.4% |
| Vandetanib | 85.1% | 99.3% | -14.2% |
| Fostamatinib | 79.9% | 97.8% | -17.9% |
| Pralsetinib | 55.7% | 99.1% | -43.4% |
| Lenvatinib | 49.0% | — | — |
| Dacomitinib | 47.5% | 99.8% | -52.3% |
| Vemurafenib | 28.6% | — | — |
| Selumetinib | 28.6% | — | — |
| Defactinib | 28.2% | 94.6% | -66.4% |
| Pacritinib | 27.0% | — | — |
| Infigratinib | 22.8% | — | — |
| Apatinib | 20.1% | — | — |
| Imatinib | 19.3% | — | — |
| Umbralisib | 19.2% | — | — |
| Leniolisib | 18.0% | — | — |
| Everolimus | 17.1% | — | — |
| Pazopanib | 17.0% | — | — |
| Ribociclib | 16.6% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_lung | Lung | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.2ms